BioCardia, Inc. (BCDA): Price and Financial Metrics
BCDA Price/Volume Stats
| Current price | $0.36 | 52-week high | $2.92 |
| Prev. close | $0.38 | 52-week low | $0.36 |
| Day low | $0.36 | Volume | 97,200 |
| Day high | $0.37 | Avg. volume | 334,421 |
| 50-day MA | $0.42 | Dividend yield | N/A |
| 200-day MA | $0.67 | Market Cap | 9.67M |
BCDA Stock Price Chart Interactive Chart >
BioCardia, Inc. (BCDA) Company Bio
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
Latest BCDA News From Around the Web
Below are the latest news stories about BIOCARDIA INC that investors may wish to consider to help them evaluate BCDA as an investment opportunity.
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection FractionSUNNYVALE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced that the first patient was enrolled and treated in its CardiALLO™ Allogeneic Mesenchymal Cell Therapy Phase I/II trial for the treatment of patients with New York Heart Association Class II and III ischemic heart failure of reduced ejection fraction (HFrEF). These “off the shelf” mese |
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation MinutesSUNNYVALE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Japan Pharmaceutical and Medical Device Agency (PMDA) minutes support the Company’s understanding that CardiAMP autologous cell therapy may be approved for the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) based on follow-up data from th |
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product ApprovalSUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update after its recent consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards approval of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure of reduced ejection fraction (HFrEF). Japan’s PMDA asked for further d |
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq RulesSUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 2,000,000 shares of the Company’s common stock at a purchase price of $0.65 per share of common stock in a registered direct offering pr |
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure StudyThe FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure. |
BCDA Price Returns
| 1-mo | -10.00% |
| 3-mo | -17.62% |
| 6-mo | -4.94% |
| 1-year | -82.09% |
| 3-year | -90.22% |
| 5-year | -96.80% |
| YTD | -45.80% |
| 2023 | -68.22% |
| 2022 | 7.73% |
| 2021 | -43.93% |
| 2020 | -5.98% |
| 2019 | -65.93% |
Continue Researching BCDA
Here are a few links from around the web to help you further your research on BioCardia Inc's stock as an investment opportunity:BioCardia Inc (BCDA) Stock Price | Nasdaq
BioCardia Inc (BCDA) Stock Quote, History and News - Yahoo Finance
BioCardia Inc (BCDA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...